about
Chutes and ladders in hepatitis C nucleoside drug developmentDiscovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5AIdentification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B proteinRandomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infectionHigh-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitorsOptimization of Benzoisothiazole dioxide inhibitory activity of the NS5B polymerase of HCV genotype 4 using ligand-steered homological modeling, reaction-driven scaffold-hopping and Enovo workflowDirect-acting antiviral agents for hepatitis C virus infection.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb bindersAntiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase.Encoded library technology screening of hepatitis C virus NS4B yields a small-molecule compound series with in vitro replicon activity.Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitorEffect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvirResistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.Anti-HCV drugs in the pipeline.Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.New targets for antiviral therapy of chronic hepatitis C.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.From the Cover: Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor.Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.Searching for anthranilic acid-based thumb pocket 2 HCV NS5B polymerase inhibitors through a combination of molecular docking, 3D-QSAR and virtual screening.Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence.In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virus RNA polymerase.Inhibition of hepatitis C virus replication by Monascus pigment derivatives that interfere with viral RNA polymerase activity and the mevalonate biosynthesis pathway.
P2860
Q26998630-2DDF6DD1-75A7-4955-8C46-109487E2B37AQ27680074-75C41B48-1B5E-4D82-8B83-5B19333A51C8Q28479254-FADF370E-2947-4D7D-A283-0A095D9E6B6CQ30418339-F15C416D-FCD0-49C8-B821-4B15017E0558Q33797808-8E501F14-CDBC-445D-97BE-A97FEE6905A2Q33948876-CCA9DFEC-5BEC-4D88-8BD2-4A35E4CD9B25Q34166105-C337FEB6-44E1-4D7F-B580-88B4B3E4FAD3Q34321440-49B6ACD3-5AB6-4B71-9FCA-700F1E81D7B1Q34420891-01755F00-492A-4587-9B56-08AC07FD032BQ34597666-6C3DB089-376F-4ED7-9A20-EDAFF9687AE0Q35139538-B301E220-3779-491F-B9BF-2ED041A5BA7DQ35590547-E9E6F601-05B5-4EB5-BF77-928B82BAAF74Q35666596-30F17F3F-6B29-4A13-ACD4-150E0734F582Q36276803-2702EADB-F103-4584-BA08-4701C3889DD5Q36558519-4D8731F0-105C-4CD2-A289-8A9C7F321ADCQ37177740-3C240F0C-C6C4-47A4-86FC-63A50F4B7E88Q37894718-DAD0EF05-C5EF-40AD-BCAB-041A27A67F04Q37972755-4014AA13-879D-4A6C-9553-F2017E9F2FC5Q38824198-C44D7E93-51EE-4433-9BD5-127737EFF16DQ38849917-E46CDE40-9172-4607-8DAD-BC5FDB6C4DFFQ40444671-2A9ED12C-A2CE-4B34-99B7-07A3C4F39DF2Q40674767-9949B4DC-26ED-49FE-A106-80A0A2C34533Q40730284-18EDCEA2-20B2-4B09-9760-B34B8D0175F9Q41681901-E3A77DD6-EDFC-4D5F-A4A4-EB18E8A11E99Q41829739-016E0611-5416-469E-8098-347316C3E46FQ42260262-C20F33AA-0973-4FCD-A53C-266C40946BA7Q42991856-1E298008-CAA5-4C7C-856E-50BD10BE06A9Q42992568-D0D7B3FE-1D08-46DE-A82F-B76E72EFEE68Q43042322-5F65A9FA-E21E-4040-8D9B-994C0D4EB540
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New NS5B polymerase inhibitors for hepatitis C.
@en
New NS5B polymerase inhibitors for hepatitis C.
@nl
type
label
New NS5B polymerase inhibitors for hepatitis C.
@en
New NS5B polymerase inhibitors for hepatitis C.
@nl
prefLabel
New NS5B polymerase inhibitors for hepatitis C.
@en
New NS5B polymerase inhibitors for hepatitis C.
@nl
P2860
P1476
New NS5B polymerase inhibitors for hepatitis C.
@en
P2093
Florence Legrand-Abravanel
Florence Nicot
P2860
P304
P356
10.1517/13543784.2010.500285
P407
P577
2010-08-01T00:00:00Z